Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Robert J. Motzer; Gary R. Hudes; Michelle S. Ginsberg; Michael S. Baum; Charles S. Harmon; Sindy T. Kim; Isan Chen; Bruce G. Redman (Profiled Author: Robert Motzer)
American Journal of Clinical Oncology: Cancer Clinical Trials. 2010;33(6):614-618.Abstract
Objectives: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors with proven clinical benefit in patients with metastatic renal cell carcinoma (RCC). This phase I/II study investigated sunitinib in combination with an epidermal growth factor receptor inhibitor, gefitinib, in patients with metastatic RCC. Methods: In phase I, patients received sunitinib 37.5 or 50 mg in 6-week cycles (4 weeks on treatment, 2 off) plus gefitinib 250 mg, both once daily, to determine the sunitinib maximum tolerated dose (MTD). Pharmacokinetics was assessed for both drugs. In phase II, patients received sunitinib MTD plus gefitinib to evaluate the safety and antitumor activity of this combination. Results: Forty-two patients were enrolled: 11 in phase I, and 31 in phase II. In phase I, 2 dose-limiting toxicities were observed with sunitinib 50 mg (grade 2 left ventricular ejection fraction decline and grade 3 fatigue), and 37.5 mg was declared the MTD. Thirteen patients treated at the MTD achieved a partial response (objective response rate: 37%; 95% confidence interval, 22-55) and 12 (34%) had stable disease. Median progression-free survival was 11 months (95% confidence interval, 6-17). The most commonly reported grade 3/4 treatmentrelated adverse event was diarrhea (14%), the only grade 3/4 adverse event to occur in <2 patients. Pharmacokinetic analyses did not indicate any drug-drug interactions. Conclusions: In metastatic RCC, sunitinib plus gefitinib demonstrated comparable efficacy to sunitinib monotherapy with an acceptable safety profile. Dosing, pharmacokinetic profile, and safety support study of sunitinib plus an epidermal growth factor receptor inhibitor in other tumor types. © 2010 by Lippincott Williams & Wilkins.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Robert J. Motzer; Thomas E. Hutson; Mark R. Olsen; Gary R. Hudes; John M. Burke; William J. Edenfield; George Wilding; Neeraj Agarwal; John A. Thompson; David Cella; et al.Journal of Clinical Oncology. 2012;30(12):1371-1377.
Ana M. Molina; Darren R. Feldman; Michelle S. Ginsberg; Glenn Kroog; Satish K. Tickoo; Xiaoyu Jia; Murielle Georges; Sujata Patil; Michael S. Baum; Victor E. Reuter; et al.Investigational New Drugs. 2012;30(1):335-340.
Brian I Rini; M Dror Michaelson; Jonathan E Rosenberg; Ronald M Bukowski; Jeffrey A Sosman; Walter M Stadler; Thomas E Hutson; Kim Margolin; Charles S Harmon; Samuel E DePrimo; et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(22):3743-3748.
Appears in this Document